In this video, Ryan Cassaday, MD, of the University of Washington, Seattle, WA, gives an overview of recent developments in the field of acute lymphoblastic leukemia (ALL). He touches upon inotuzumab ozogamicin, and discusses the CD3/CD19 bispecific T-cell engager blinatumomab in more depth, suggesting avenues for future research to understand how therapy sequence, biomarker screening and transplant can be optimized relative to this therapy. Finally, he discusses CAR T-cells, and the goal to increase the range of patients for whom they are an approved therapy. This interview took place at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
ALL: recent immunotherapeutic developments
